EDAP TMS SA
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $13.20M | $-0.38 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $17.80M | $-0.24 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | Before market open | $18.90M | $-0.22 | – |
Company guidance
Outlook given with results on Aug 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Total revenue | 2026 | $50.00M to $54.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Edap Tms filed with the SEC
Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Results for Second Quarter of 2026
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Global Leader in Therapeutic Ultrasound
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
2026 Investor Day Nasdaq (FOCL) June 1, 2026 1
Regulation FD disclosure · EX-99.1 to Form 8-K
EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive
Other events · EX-99.1 to Form 8-K
EDAP Reports Strong Financial Results with Record First Quarter HIFU
Results of operations · EX-99.1 to Form 8-K
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue
Results of operations · EX-99.1 to Form 8-K
The Global Leader in Therapeutic Ultrasound 1
Regulation FD disclosure · EX-99.1 to Form 8-K
EDAP Announces Appointment of David Horn to
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EDAP Announces Preliminary Record Fourth Quarter and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
9 9 Focal One Answers an Unmet Need for a Large Underserved Patient Population PROSTATE CANCER Focal One HIFU Focal One HIFU First - Line Treatment Progression from Active Surveillance Salvage Treatment
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Contract number (FI No): 99053
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EDAP Secures €36 Million Credit Facility from European Investment
EX-99.3 to Form 6-K